Handel GlaxoSmithKline PLC - GSKl CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.040 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.028007% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.015829% | ||||||||
| Gebyr natten over, tid | 22:00 (UTC) | ||||||||
| Min. handlet mængde | 0.1 | ||||||||
| Valuta | GBP | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
GSK plc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 14.565 |
| Åben* | 14.66 |
| 1-Års Ændring* | -10.28% |
| Dagens Spænd* | 14.66 - 14.94 |
| 52-Ugers Spænd | 12.81-18.43 |
| Gennemsnitlig Volumen (10 dage) | 13.47M |
| Gennemsnitlig Volumen (3 måneder) | 176.07M |
| Market Cap | 60.83B |
| P/E-forhold | 13.60 |
| Udestående aktier | 4.09B |
| Omsætning | 29.32B |
| EPS | 1.09 |
| Dividend (Udbytte %) | 6.05816 |
| Beta | 0.57 |
| Næste indtjeningsopgørelse | Apr 26, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Feb 7, 2023 | 14.835 | 0.245 | 1.68% | 14.590 | 14.945 | 14.580 |
| Feb 6, 2023 | 14.565 | 0.280 | 1.96% | 14.285 | 14.660 | 14.240 |
| Feb 3, 2023 | 14.390 | 0.255 | 1.80% | 14.135 | 14.495 | 14.135 |
| Feb 2, 2023 | 14.310 | 0.080 | 0.56% | 14.230 | 14.355 | 14.055 |
| Feb 1, 2023 | 14.190 | -0.130 | -0.91% | 14.320 | 14.430 | 14.030 |
| Jan 31, 2023 | 14.270 | 0.145 | 1.03% | 14.125 | 14.330 | 14.055 |
| Jan 30, 2023 | 14.130 | 0.145 | 1.04% | 13.985 | 14.260 | 13.985 |
| Jan 27, 2023 | 14.100 | 0.065 | 0.46% | 14.035 | 14.215 | 14.035 |
| Jan 26, 2023 | 14.025 | 0.040 | 0.29% | 13.985 | 14.140 | 13.980 |
| Jan 25, 2023 | 13.995 | 0.040 | 0.29% | 13.955 | 14.040 | 13.920 |
| Jan 24, 2023 | 13.930 | -0.150 | -1.07% | 14.080 | 14.125 | 13.835 |
| Jan 23, 2023 | 14.120 | 0.075 | 0.53% | 14.045 | 14.170 | 14.040 |
| Jan 20, 2023 | 14.035 | -0.160 | -1.13% | 14.195 | 14.195 | 14.005 |
| Jan 19, 2023 | 14.165 | 0.095 | 0.68% | 14.070 | 14.215 | 14.025 |
| Jan 18, 2023 | 14.130 | -0.155 | -1.09% | 14.285 | 14.290 | 14.015 |
| Jan 17, 2023 | 14.375 | 0.010 | 0.07% | 14.365 | 14.400 | 14.275 |
| Jan 16, 2023 | 14.375 | 0.150 | 1.05% | 14.225 | 14.400 | 14.225 |
| Jan 13, 2023 | 14.365 | 0.270 | 1.92% | 14.095 | 14.415 | 14.095 |
| Jan 12, 2023 | 14.325 | 0.205 | 1.45% | 14.120 | 14.330 | 14.090 |
| Jan 11, 2023 | 14.095 | 0.010 | 0.07% | 14.085 | 14.245 | 14.065 |
GlaxoSmithKline PLC Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total omsætning | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
| Omsætning | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
| Kost af omsætning, Total | 8898 | 9317 | 9572 | 10168 | 10890 | 11427 |
| Bruttofortjeneste | 18991 | 20869 | 21249 | 23586 | 23209 | 22687 |
| Totale Driftsudgifter | 25291 | 26005 | 25335 | 26793 | 26316 | 27949 |
| Salgs/Generelle/Admin. Udgifter, Total | 8859 | 9341 | 9408 | 10671 | 10717 | 10225 |
| Forskning & Udvikling | 3468 | 3862 | 3726 | 4338 | 4603 | 4776 |
| Depreciation / Amortization | 41 | 45 | 44 | 64 | 76 | 101 |
| Renteudgift (Indkomst) - Netto Drift | 3664 | 2139 | 1839 | -128 | 1220 | 1073 |
| Usædvanlig Udgift (Indkomst) | 782 | 1666 | 1038 | 2051 | -807 | 772 |
| Other Operating Expenses, Total | -421 | -365 | -292 | -371 | -383 | -425 |
| Driftsindtægter | 2598 | 4181 | 5486 | 6961 | 7783 | 6165 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -628 | -646 | -602 | -708 | -432 | -1317 |
| Andre, Netto | -31 | -10 | -84 | -32 | -383 | 594 |
| Netto Indkomst Før Skat | 1939 | 3525 | 4800 | 6221 | 6968 | 5442 |
| Netto Indkomst Efter Skat | 1062 | 3247 | 3921 | 5268 | 6388 | 5096 |
| Minoritetsrente | -150 | -637 | -423 | -623 | -639 | -711 |
| Netto Indkomst Før Ekstra Ting | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
| Netto Indkomst | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Fortyndelsesændring | 1.074 | 0 | ||||
| Fortyndet Netto Indkomst | 913.074 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Fortyndet Vægtet Gennemsnit Aktier | 4909 | 4941 | 4971 | 5016 | 5038 | 5065 |
| Fortyndet EPS Uden Ekstraordinære Ting | 0.186 | 0.52823 | 0.70368 | 0.92604 | 1.14113 | 0.86575 |
| Dividends per Share - Common Stock Primary Issue | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| Fortyndet Normaliseret EPS | 0.32758 | 0.94697 | 0.85456 | 1.35566 | 0.9736 | 0.87285 |
| Totale Ekstraordinære Ting | -1078 | 125 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 7418 | 8092 | 9077 | 9527 | 9780 |
| Omsætning | 7418 | 8092 | 9077 | 9527 | 9780 |
| Kost af omsætning, Total | 2411 | 2519 | 2822 | 3675 | 3645 |
| Bruttofortjeneste | 5007 | 5573 | 6255 | 5852 | 6135 |
| Totale Driftsudgifter | 5725 | 6453 | 7139 | 8632 | 6979 |
| Salgs/Generelle/Admin. Udgifter, Total | 2315 | 2498 | 2504 | 2908 | 2681 |
| Forskning & Udvikling | 1077 | 1165 | 1169 | 1363 | 1154 |
| Depreciation / Amortization | 26 | 25 | 25 | 25 | 23 |
| Usædvanlig Udgift (Indkomst) | -13 | 323 | 735 | 796 | -385 |
| Other Operating Expenses, Total | -91 | -77 | -116 | -135 | -139 |
| Driftsindtægter | 1693 | 1639 | 1938 | 895 | 2801 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -175 | -169 | -190 | -189 | -203 |
| Netto Indkomst Før Skat | 1518 | 1470 | 1748 | 706 | 2598 |
| Netto Indkomst Efter Skat | 1260 | 1538 | 1368 | 930 | 2167 |
| Minoritetsrente | -187 | -143 | -200 | -181 | -365 |
| Netto Indkomst Før Ekstra Ting | 1073 | 1395 | 1168 | 749 | 1802 |
| Netto Indkomst | 1073 | 1395 | 1168 | 749 | 1802 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1073 | 1395 | 1168 | 749 | 1802 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1073 | 1395 | 1168 | 749 | 1802 |
| Fortyndelsesændring | 0 | ||||
| Fortyndet Netto Indkomst | 1073 | 1395 | 1168 | 749 | 1802 |
| Fortyndet Vægtet Gennemsnit Aktier | 5037 | 5060 | 5060 | 5074 | 5068 |
| Fortyndet EPS Uden Ekstraordinære Ting | 0.21302 | 0.27569 | 0.23083 | 0.14762 | 0.35556 |
| Dividends per Share - Common Stock Primary Issue | 0.19 | 0.19 | 0.19 | 0.23 | 0.14 |
| Fortyndet Normaliseret EPS | 0.19873 | 0.25375 | 0.3419 | 0.22566 | 0.2717 |
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 16711 | 15907 | 16927 | 19491 | 20247 | 18674 |
| Likvider og Kortsigtede Investeringer | 4986 | 3911 | 3958 | 4786 | 6370 | 4335 |
| Cash | 1462 | 826 | 569 | 795 | 1762 | 1427 |
| Kortsigtede Investeringer | 3524 | 3085 | 3389 | 3991 | 4608 | 2908 |
| Totale Tilgodehavender, Netto | 5917 | 5950 | 6322 | 7148 | 7264 | 8031 |
| Accounts Receivable - Trade, Net | 4679 | 4693 | 5185 | 5494 | 5562 | 6258 |
| Total Inventory | 5102 | 5557 | 5476 | 5947 | 5996 | 5783 |
| Prepaid Expenses | 335 | 308 | 330 | 316 | 359 | 315 |
| Other Current Assets, Total | 371 | 181 | 841 | 1294 | 258 | 210 |
| Total Assets | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
| Property/Plant/Equipment, Total - Net | 10808 | 10860 | 11058 | 11314 | 11006 | 10672 |
| Property/Plant/Equipment, Total - Gross | 22164 | 21719 | 22488 | 22565 | 22313 | 21518 |
| Accumulated Depreciation, Total | -11356 | -10859 | -11430 | -11251 | -11307 | -10846 |
| Goodwill, Net | 5965 | 5734 | 5789 | 10562 | 10597 | 10552 |
| Intangibles, Net | 18776 | 17562 | 17202 | 30955 | 29824 | 30079 |
| Long Term Investments | 1248 | 1101 | 1558 | 2151 | 3424 | 2214 |
| Note Receivable - Long Term | 886 | 875 | 816 | 893 | 858 | 935 |
| Other Long Term Assets, Total | 4687 | 4342 | 4716 | 4326 | 4475 | 5977 |
| Total Current Liabilities | 19001 | 26569 | 22491 | 24050 | 22148 | 23670 |
| Accounts Payable | 3596 | 3528 | 3645 | 4144 | 4357 | 4535 |
| Accrued Expenses | 6444 | 6929 | 8535 | 9111 | 9753 | 11186 |
| Notes Payable/Short Term Debt | 1426 | 765 | 4420 | 5020 | 1145 | 802 |
| Current Port. of LT Debt/Capital Leases | 2703 | 2060 | 1373 | 1898 | 2580 | 2799 |
| Other Current Liabilities, Total | 4832 | 13287 | 4518 | 3877 | 4313 | 4348 |
| Total Liabilities | 57957 | 56449 | 53706 | 68287 | 65844 | 64048 |
| Total Long Term Debt | 14661 | 14264 | 20271 | 23590 | 23425 | 20572 |
| Long Term Debt | 14620 | 14221 | 20227 | 22580 | 22538 | 19760 |
| Capital Lease Obligations | 41 | 43 | 44 | 1010 | 887 | 812 |
| Deferred Income Tax | 1934 | 1396 | 1156 | 3810 | 3600 | 3556 |
| Minority Interest | 3839 | 3557 | -688 | 6952 | 6221 | 6287 |
| Other Liabilities, Total | 18522 | 10663 | 10476 | 9885 | 10450 | 9963 |
| Total Equity | 1124 | -68 | 4360 | 11405 | 14587 | 15055 |
| Common Stock | 1342 | 1343 | 1345 | 1346 | 1346 | 1347 |
| Additional Paid-In Capital | 2954 | 3019 | 3091 | 3174 | 3281 | 3301 |
| Retained Earnings (Accumulated Deficit) | -3263 | -4348 | -8 | 6659 | 8884 | 10073 |
| ESOP Debt Guarantee | -286 | -400 | -161 | -135 | -195 | -28 |
| Unrealized Gain (Loss) | 380 | 329 | 140 | 409 | 1302 | 383 |
| Other Equity, Total | -3 | -11 | -47 | -48 | -31 | -21 |
| Total Liabilities & Shareholders’ Equity | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
| Total Common Shares Outstanding | 4910.11 | 4957.95 | 4922.93 | 4953.23 | 5029.98 | 5031.81 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 18524 | 17566 | 18254 | 18674 | 28988 |
| Likvider og Kortsigtede Investeringer | 4817 | 3562 | 3514 | 4335 | 13977 |
| Likvider & Lignende | 4757 | 3503 | 3453 | 4274 | 10967 |
| Kortsigtede Investeringer | 60 | 59 | 61 | 61 | 3010 |
| Totale Tilgodehavender, Netto | 7183 | 7507 | 8284 | 8346 | 8797 |
| Accounts Receivable - Trade, Net | 6492 | 6902 | 7697 | 7860 | 8300 |
| Total Inventory | 6216 | 6330 | 6244 | 5783 | 6003 |
| Other Current Assets, Total | 308 | 167 | 212 | 210 | 211 |
| Total Assets | 78079 | 77011 | 78689 | 79103 | 89689 |
| Property/Plant/Equipment, Total - Net | 10633 | 10589 | 10667 | 10672 | 10704 |
| Goodwill, Net | 10442 | 10435 | 10582 | 10552 | 10705 |
| Intangibles, Net | 29418 | 29333 | 30241 | 30079 | 30468 |
| Long Term Investments | 3755 | 3235 | 2818 | 2214 | 1739 |
| Other Long Term Assets, Total | 5307 | 5853 | 6127 | 6912 | 7085 |
| Total Current Liabilities | 20275 | 21387 | 22417 | 23670 | 24278 |
| Payable/Accrued | 14610 | 14267 | 15230 | 17554 | 17577 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3172 | 5041 | 4869 | 3601 | 4102 |
| Other Current Liabilities, Total | 2493 | 2079 | 2318 | 2515 | 2599 |
| Total Liabilities | 63214 | 61634 | 63263 | 64048 | 73508 |
| Total Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
| Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
| Deferred Income Tax | 3566 | 3587 | 3666 | 3556 | 3668 |
| Minority Interest | 6145 | 6201 | 6322 | 6287 | 6451 |
| Other Liabilities, Total | 10181 | 10017 | 10122 | 9963 | 9885 |
| Total Equity | 14865 | 15377 | 15426 | 15055 | 16181 |
| Common Stock | 1346 | 1347 | 1347 | 1347 | 1347 |
| Additional Paid-In Capital | 3296 | 3299 | 3300 | 3301 | 3436 |
| Retained Earnings (Accumulated Deficit) | 10223 | 10731 | 10779 | 10407 | 11398 |
| Total Liabilities & Shareholders’ Equity | 78079 | 77011 | 78689 | 79103 | 89689 |
| Total Common Shares Outstanding | 5031.39 | 5031.68 | 5031.74 | 5031.81 | 5083.9 |
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto indkomst/Startlinje | 1062 | 2169 | 4046 | 5268 | 6388 | 5096 |
| Likvider Fra Driftsaktiviteter | 6497 | 6918 | 8421 | 8020 | 8441 | 7952 |
| Likvider Fra Driftsaktiviteter | 978 | 988 | 954 | 1231 | 1214 | 1195 |
| Amortization | 796 | 934 | 902 | 1103 | 1137 | 1182 |
| Ikke-Likvide Ting | 1641 | 3072 | 1406 | 2416 | -305 | 1381 |
| Cash Taxes Paid | 1609 | 1340 | 1326 | 1512 | 1655 | 1291 |
| Likvid Rente Betalt | 732 | 781 | 766 | 895 | 864 | 786 |
| Ændringer i Driftskapital | 2020 | -245 | 1113 | -1998 | 7 | -902 |
| Likvider fra Investeringsaktiviteter | -1269 | -1443 | -1553 | -5354 | 2161 | -1777 |
| Kapitaludgifter | -2352 | -2202 | -1796 | -2163 | -2239 | -2931 |
| Andre Investerings-Cash-Flow-Ting, Total | 1083 | 759 | 243 | -3191 | 4400 | 1154 |
| Likvider fra Financieringsaktiviteter | -6392 | -6380 | -6389 | -1840 | -10132 | -7589 |
| Financiering af Cash-Flow-Ting | -1687 | -1475 | -10660 | -1453 | -1950 | -1401 |
| Total Cash Dividends Paid | -4850 | -3906 | -3927 | -3953 | -3977 | -3999 |
| Udstedelse (Pensionering) af Aktier, Netto | 15 | -9 | 74 | 51 | 29 | 21 |
| Udstedelse (Pensionering) af Gæld, Netto | 130 | -990 | 8124 | 3515 | -4234 | -2210 |
| Udenlandsk Børs Effekter | 283 | -100 | 8 | -82 | -39 | -29 |
| Netto Ændring i Likviditet | -881 | -1005 | 487 | 744 | 431 | -1443 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1260 | 2798 | 4166 | 5096 | 2167 |
| Cash From Operating Activities | 331 | 1623 | 4185 | 7952 | 2542 |
| Cash From Operating Activities | 361 | 1025 | 2011 | 2377 | 704 |
| Non-Cash Items | 433 | 570 | 1140 | 1381 | 634 |
| Cash Taxes Paid | 155 | 700 | 857 | 1291 | 213 |
| Cash Interest Paid | 95 | 439 | 486 | 786 | 85 |
| Changes in Working Capital | -1723 | -2770 | -3132 | -902 | -963 |
| Cash From Investing Activities | -48 | -233 | -1416 | -1777 | -3593 |
| Capital Expenditures | -354 | -1015 | -2299 | -2931 | -601 |
| Other Investing Cash Flow Items, Total | 306 | 782 | 883 | 1154 | -2992 |
| Cash From Financing Activities | -1376 | -3421 | -4815 | -7589 | 7973 |
| Financing Cash Flow Items | -391 | -883 | -1052 | -1401 | 16 |
| Total Cash Dividends Paid | -946 | -2097 | -3048 | -3999 | -952 |
| Issuance (Retirement) of Stock, Net | 15 | 19 | 20 | 21 | 12 |
| Issuance (Retirement) of Debt, Net | -54 | -460 | -735 | -2210 | 8897 |
| Foreign Exchange Effects | -35 | -34 | -21 | -29 | 12 |
| Net Change in Cash | -1128 | -2065 | -2067 | -1443 | 6934 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5959 | 229134683 | -34164923 | 2022-07-19 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.1513 | 129037070 | 1316706 | 2022-11-29 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3261 | 95245653 | 977516 | 2023-01-01 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 1.9416 | 79502299 | 0 | 2022-02-27 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2735 | 52145714 | 113556 | 2023-01-01 | LOW |
| Silchester International Investors, L.L.P. | Investment Advisor/Hedge Fund | 1.2688 | 51954188 | 12827890 | 2022-11-28 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.2106 | 49570121 | -418206 | 2023-01-01 | LOW |
| Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.9197 | 37659407 | -1831852 | 2022-11-28 | LOW |
| Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.8804 | 36048753 | 1255452 | 2023-01-01 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8357 | 34220716 | -131359 | 2023-01-01 | LOW |
| Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.7629 | 31239940 | 2050203 | 2023-01-01 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5453 | 22328352 | 526606 | 2022-11-29 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5138 | 21037527 | -869474 | 2022-11-28 | LOW |
| Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.4996 | 20457122 | 1270578 | 2022-11-28 | LOW |
| Independent Franchise Partners LLP | Investment Advisor | 0.4732 | 19376797 | 6500373 | 2022-11-29 | LOW |
| Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.4639 | 18995200 | -674014 | 2023-01-01 | LOW |
| GlaxoSmithKline Plc ESOP | Corporation | 0.4534 | 18564231 | -20616012 | 2021-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.4354 | 17828669 | -58801534 | 2022-11-29 | LOW |
| Mondrian Investment Partners Ltd. | Investment Advisor | 0.4144 | 16967070 | -246648 | 2022-11-29 | LOW |
| Schweizerische Nationalbank | Bank and Trust | 0.4129 | 16908425 | -1156909 | 2022-11-28 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group +500000+
Handlende
93000+
Månedlkige, aktive klienter
$57000000+
Månedlig investeringsvolumen
$31000000+
Prøv nu Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelskurtage
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Gearing
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
GSK Company profile
Om GlaxoSmithKline PLC
GlaxoSmithKline PLC er en global virksomhed inden for sundhedssektoren. Virksomheden forsker i og udvikler en række produkter inden for tre hovedområder: Lægemidler, vacciner og sundhedspleje for forbrugere. Virksomhedens produktformuleringer omfatter tabletter, cremer/salver, inhalatorer, injektioner, væsker og sterile produkter. Virksomhedens lægemiddelvirksomhed har en portefølje af etablerede lægemidler inden for respiratoriske sygdomme, human immundefektvirus (HIV), immunoinflammation og onkologi. Virksomhedens Vaccines har en portefølje af vacciner, der hjælper med at beskytte mennesker mod en række sygdomme hele livet igennem. Virksomhedens vacciner bekæmper sygdomme som f.eks. pneumokokker, meningitis, hepatitis, rotavirus, kighoste og influenza. Forretningsområdet Consumer Healthcare kombinerer videnskab og forbrugerindsigt for at skabe mærker til dagligdags sundhedspleje, som forbrugerne har tillid til, og som eksperter anbefaler inden for mundhygiejne, smertelindring, forkølelse, influenza og allergi, fordøjelsessundhed samt vitaminer, mineraler og kosttilskud.
| Industry: | Pharmaceuticals (NEC) |
980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com